

SUVEN Life Sciences Ltd



News Release

Suven spends 29.78% of Revenue on R&D for the quarter ending Sep 09

HYDERABAD, INDIA (Oct' 31, 2009): SUVEN LIFE Sciences Limited is a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its unaudited financial results for the quarter ended Sept 2009. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on Oct 31, 2009 at Hyderabad.

Financial Highlights for the quarter ended Sept 2009:

Growth in revenue -14.03% (Rs 332 mil vs. Rs 386 mil)
Growth in PAT -47.94% (Rs 25.16 mil vs. Rs 48.34 mil)
Growth in EBIDTA -51.46% (Rs 40.9 mil vs. Rs 84.31 mil)

The revenues for the half year ended Sept 2009 stood at Rs.644.84 mil compared to Rs.708.06 mil for the corresponding previous period. PAT for the period stood at Rs. 47 mil compared to Rs. 64.33 mil for the corresponding previous period.

Suven's major thrust on innovative R&D in Drug Discovery continues with a total spending of Rs 172.76 mil for the half year ended Sept 2009 constituting 26.79 % of revenue with a revenue R&D expenditure of Rs 141.46 mil recording about 21.94% of revenue for the half year.

Suven's drug **discovery pipeline consists of 10 molecules** on 6 targets in CNS arena which are at various stages of discovery and development. Out of the 10 molecules SUVN-502 is a lead clinical candidate which has successfully finished Phase 1 clinical trial and currently undergoing bridge toxicology studies which will enable it to move into proof of Concept (PoC) stage in the year 2010. In addition to this there are 3 molecules in the final stages of preclinical activity which will move into IND (Phase 1) stage during the year 2010-11. All other 6 molecules are at various stages of preclinical development.

Suven's drug discovery collaboration in central nervous system (CNS) disorder with Eli Lilly and company yielded a positive outcome with lead declaration leading to a milestone payment to Suven during this quarter and hoping to achieve another milestone before the end of the fiscal year.

For more information on Suven, please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;